Home > Cardiology > Experimental drug lowers risk of cardiovascular, renal events in type 2 diabetics

Experimental drug lowers risk of cardiovascular, renal events in type 2 diabetics


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
The New England Journal of Medicine
Reuters Health - 28/06/2021 - Among type 2 diabetics who had a history of -- or were at risk for -- heart or kidney disease, treatment with the experimental diabetes drug efpeglenatide lowered the risk of a first major cardiovascular event by 27% and slashed the odds of a renal event by 32%, according to the results of a new study. After a median follow-up of 1.8 years, a major cardiovascular event such as a heart attack or stroke occurred in 7.0% of those getting weekly subcutaneous injections of the drug versus 9.2% of volunteers getting placebo injections (P=0.007 for superiority). When the research team, led by Dr. Hertzel Gerstein of McMaster University and Hamilton Health Services in Ontario, Canada, looked at renal problems, such as macroalbuminuria or a decrease in kidney function, the rates were 13.0% in the efpeglenatide group versus 18.4% with placebo (P<0.001). Sanofi paid for the study, known as AMPLITUDE-O. Its results were published online b...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on